Biotech Values

[vinmantoo]

Dew

<From a strictly mathematical standpoint, the ballooning number of cancer-drug candidates is bearish in the aggregate for investors in biotech companies that are focused entirely in this area.>

Yes that makes sense. I also think it is worse for big pharma as they need the big blockbusters. With tumor typing the market for a drug gets split, making it harder to achieve or hold blockbuster status.